SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Adverum Biotechnologies, Inc. (ADVM)
Last adverum biotechnologies, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
adverum.gcs-web.com/investor-overview
Company Research
Source: PR Newswire
NEW YORK, March 2, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ: ADVM). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.The investigation concerns whether Adverum and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On September 12, 2019, Adverum issued a press release announcing clinical data from the OPTIC Phase 1 clinical trial of the Company's product ADVM-022 as a treatment for wet age-related macular degeneration. Among other data, Adverum disclosed that patients taking ADVM-022 suffered significant deterioration in their sight. On this news, Adverum's stock price fell $6.04 per share, or 50.33%, to close at $5.96 per share on September 12, 2019.The Pomerantz Firm, with offices in New
Show less
Read more
Impact Snapshot
Event Time:
ADVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADVM alerts
High impacting Adverum Biotechnologies, Inc. news events
Weekly update
A roundup of the hottest topics
ADVM
News
- Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements [Yahoo! Finance]Yahoo! Finance
- Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design ElementsGlobeNewswire
ADVM
Earnings
- 8/12/24 - Beat
ADVM
Sec Filings
- 11/18/24 - Form 8-K
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- ADVM's page on the SEC website